These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19622825)

  • 1. Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice.
    Petersen RC; Trojanowski JQ
    JAMA; 2009 Jul; 302(4):436-7. PubMed ID: 19622825
    [No Abstract]   [Full Text] [Related]  

  • 2. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away.
    Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612
    [No Abstract]   [Full Text] [Related]  

  • 3. A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease.
    Barichello T; Giridharan VV; Dal-Pizzol F
    Braz J Psychiatry; 2019; 41(6):467-468. PubMed ID: 31826090
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
    Dean RA; Shaw LM
    Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
    [No Abstract]   [Full Text] [Related]  

  • 5. Lumbar drains can affect CSF biomarker levels.
    Craven CL; Chapman MD; D'Antona L; Thompson SD; Lakdawala N; Zetterberg H; Watkins LD; Toma AK
    J Clin Pathol; 2019 Jan; 72(1):91-92. PubMed ID: 29997233
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comments on the article by K. Buch et al. Tau protein: a potential biological marker for early detection of Alzheimer disease. Nervenarzt (1998) 69:379-385].
    Otto M; Wiltfang J; Poser S; Kornhuber J
    Nervenarzt; 1999 Jul; 70(7):668-70. PubMed ID: 10434268
    [No Abstract]   [Full Text] [Related]  

  • 7. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.
    Pijnenburg YA; Schoonenboom NS; Scheltens P
    Neurology; 2003 Jan; 60(2):353-4; author reply 353-4. PubMed ID: 12552068
    [No Abstract]   [Full Text] [Related]  

  • 8. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.
    Andreasson U; Lautner R; Schott JM; Mattsson N; Hansson O; Herukka SK; Helisalmi S; Ewers M; Hampel H; Wallin A; Minthon L; Hardy J; Blennow K; Zetterberg H
    Mol Psychiatry; 2014 Feb; 19(2):148-9. PubMed ID: 23419830
    [No Abstract]   [Full Text] [Related]  

  • 9. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
    Blennow K; Zetterberg H
    Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers in Alzheimer's disease clinical trials.
    Zetterberg H; Mattsson N; Shaw LM; Blennow K
    Biomark Med; 2010 Feb; 4(1):91-8. PubMed ID: 20387305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?
    Papaliagkas VT
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):70-8. PubMed ID: 23489287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Blennow K; Trojanowski JQ
    Clin Chem; 2022 Oct; 68(10):1336-1337. PubMed ID: 36103266
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.
    Blennow K; Zetterberg H
    Nat Med; 2015 Mar; 21(3):217-9. PubMed ID: 25742456
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K
    Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CSF Tau is associated with psychosis in Alzheimer's disease.
    Koppel J; Sunday S; Buthorn J; Goldberg T; Davies P; Greenwald B;
    Am J Psychiatry; 2013 Oct; 170(10):1212-3. PubMed ID: 24084821
    [No Abstract]   [Full Text] [Related]  

  • 16. Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?
    Lehmann S; Gabelle A; Paquet C
    Alzheimers Dement; 2015 Sep; 11(9):1125-6. PubMed ID: 25457432
    [No Abstract]   [Full Text] [Related]  

  • 17. Cerebrospinal fluid markers for prediction of Alzheimer's disease.
    Zetterberg H; Wahlund LO; Blennow K
    Neurosci Lett; 2003 Nov; 352(1):67-9. PubMed ID: 14615052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.
    Le Bastard N; Van Buggenhout M; De Leenheir E; Martin JJ; De Deyn PP; Engelborghs S
    J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):923-4; author reply 924-5. PubMed ID: 17702886
    [No Abstract]   [Full Text] [Related]  

  • 19. Alzheimer's disease CSF biomarkers: clinical indications and rational use.
    Niemantsverdriet E; Valckx S; Bjerke M; Engelborghs S
    Acta Neurol Belg; 2017 Sep; 117(3):591-602. PubMed ID: 28752420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Searched for and found: non-demented patients with Alzheimer's disease].
    Engelborghs S
    Tijdschr Psychiatr; 2011; 53(9):654-6. PubMed ID: 21898323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.